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Background: Tumor-induced osteomalacia (TIO) is a rare syndrome typically caused by mesenchymal tumors. It has
been shown that complete tumor resection may be curative. However, to our knowledge, there has been no report
of a large cohort to exam different surgical approaches. This study was aimed to assess outcomes of different
surgical options of patients with tumor-induced osteomalacia at a single institution.
Methods: Patients with extremity tumors treated in our hospital from January, 2004 to July, 2012 were identified.
The minimum follow-up period was 12 months. Patient’s demography, tumor location, preoperative preparation,
type of surgeries were summarized, and clinical outcomes were recorded. Successful treatment was defined as
significant symptom improvement, normal serum phosphorus and significant improvement or normalization of
bone mineral density at the last follow-up. Differences between patients with soft tissue tumors and bone tumors
were compared.
Results: There were 40 (24 male and 16 female) patients identified, with an average age of 44 years. The tumors
were isolated in either soft tissue (25 patients) or bone (12 patients) and combined soft tissue and bone invasion
was observed in 3 patients. For the primary surgery, tumor resection and tumor curettage were performed. After
initial surgical treatment, six patients then received a second surgery. Four patients were found to have malignant
tumors base on histopathology. With a minimum follow-up period of 12 months, 80% of patients (32/40) were
treated successfully, including 50% of patients (2/4) with malignant tumors. Compared to patients with bone tumor,
surgical results were better in patient with soft tissue tumor.
Conclusions: Surgical treatment was an effective way for TIO. Other than tumor curettage surgery, tumor resection
is the preferred options for these tumors.
Keywords: Tumor-induced osteomalacia, Surgical treatment, Extremity, Tumor resectionBackground
Tumor-induced osteomalacia (TIO), also known as onco-
genic osteomalacia, is a rare syndrome characterized by
hypophosphatemia, hyperphosphaturia, reduced 1,25-dihy-
droxyvitamin D concentration, and osteomalacia caused by
typical benign mesenchymal tumors [1,2]. The pathogenic
tumor secretes so-called phosphatonins [3], such as fibro-
blast growth factor 23 (FGF23) [4], frizzled related protein-
4 [5], matrix extracellular phosphoglycoprotein [6] and* Correspondence: jinjin9010@126.com
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unless otherwise stated.FGF7 [7], which causes reduced reabsorption of phosphate
in the proximal renal tubule. To date, FGF23 is thought to
be the primary clinically relevant phosphatonin [8].
Locating the tumor is often challenging as it is often
small in size and may be widely distributed. Functional
imaging, including octreotide scintigraphy [9] and posi-
tron emission tomography along with computed tomog-
raphy (PET/CT) [10], anatomical images, including
magnetic resonance imaging (MRI), computed tomog-
raphy (CT) and ultrasonography (USG), and venous
sampling [10,11] have been used. Once the tumor isis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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should be planned.
To our knowledge, no study has examined the efficacy
of different surgical approaches of TIO in a large cohort
perhaps due to rarity and wide distribution of the tu-
mors. Depending on the anatomical location of the
tumor, surgery is often performed by different special-
ties, including orthopedists, otorhinolaryngologists, den-
tists, urologists and thoracic surgeons [12,13]. Owing to
the anatomical features of the tumor, preoperative prep-
aration and choices of surgical approaches are also dif-
ferent. We reported our experience of bone and/or soft
tissue tumors of the extremities in our institution. The
primary aim of this study was to evaluate the overall
outcomes of different surgical treatment and to deter-
mine the preferred surgical options. The second aim was
to compare the surgical outcomes between soft tissue
tumor and bone tumor.Methods
Patients
We performed a retrospective review of TIO patients with
bone and/or soft tissue tumors located at either upper or
lower extremities. Patients with tumors in the maxillo-
facial region or visceral organs were not included in
current study. From January, 2004 to July, 2012, 40 TIO
patients with extremity tumors and treated surgically at
our hospital were identified. Patients’ medical records, sur-
gical procedures including preoperative preparations, and
pathology reports were reviewed. This study was approved
by the institutional review board of Peking Union Medical
College Hospital. And written informed consent was ob-
tained from all participants in the study.Figure 1 A 63 year-old male patient complained bone pain and fatigu
25-dihydroxyvitamin D (14.4 pg/mL) was observed, and 24-hour urine phos
99Tcm-OCT showed high expression of somatostatin receptor in his right kn
and serum phosphorus returned to normal eight days after surgery. ClinicaPreoperative preparation
All patients suspected of TIO were referred to our
Orthopedic department from the Endocrinology depart-
ment. Multiple imaging modalities were used to identify
tumor, including functional studies (octreotide scintig-
raphy and/or PET/CT) and anatomic studies (CT, USG
and/or MRI) [12].
Operative procedure
Tumor biopsy was not performed before removal of the
tumor for the following reasons: (1) the tumor is usually
small and is not biopsiable prior to excision; (2) the
tumor is typically characterized as phosphaturic mesen-
chymal tumor (PMT) and malignant tumors are rarely
seen. If pathology after surgery suggested a malignant
tumor, a secondary operation with extensive margins
would be offered.
For soft tissue tumor, complete tumor, including the
integrated capsule, was resected. If the tumor was close
to bone margin and bone involvement could not be ex-
cluded, part of the cortical bone was also removed.
If the tumor was located in skeletal tissue, extensive
tumor curettage and bone allograft was usually per-
formed at the initial surgery with curettage extending
for at least 5 mm from the presumed tumor margin ac-
cording to MRI due to concern about surgical morbidity
with complete resection. Yet it should be done cau-
tiously to not breach the cortical bone. A typical case
was given in Figure 1. If the tumor was not completely
removed in first surgery, tumor resection and custom-
made artificial prosthesis replacement was offered. With
this surgical approach, the complete tumor with at least
20 mm margins would be resected. For patients not suit-
able for prosthesis replacement or for those who refused,e for five year. Decreased serum phosphorus (0.39 mmol/L) and 1,
phate and TMP/GRF was 19.5 mg and 0.56 mg/dL, respectively. (a)
ee (black arrow). (b) Curettage and bone allograft were performed
l symptoms were significantly improved at one year follow-up.
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attempted. In cases where tumor curettage was difficult,
tumor resection and prosthesis replacement would be
performed as the first option. The resection range would
include at least 20 mm normal tissues to the tumor mar-
gin. For the tumor infiltrating both soft tissue and bone,
extensive tumor resection and curettage was performed.
If the histopathology after surgery suggested the tumor
was malignant, extensive tumor resection with more
normal tissues to the tumor margin was suggested. For
patients with extensive tumor involvement, amputation
was recommended.
Postoperative monitoring and follow-up
Serum phosphorus was routinely tested 2 hours, 6 hours,
12 hours, 24 hours, 48 hours, 72 hours, 5 days, and
7 days after surgery, and then every 2–3 days until
serum phosphorus levels became normal or patients
were discharged. FGF-23 was not measured because we
lacked the capability to routinely do so.
For the patients whose pathological result indicated a
malignant tumor, a second surgery would be suggested
and local radiotherapy was scheduled as necessary.
All the patients were asked to follow-up 3 months
after surgery at orthopedic and endocrine clinics, and
then every 6–12 months. Secum phosphorus, 1, 25-
dihydroxyvitamin D and bone mineral density (evaluated
by dual-energy X-ray bone density screening) were regu-
larly monitored during the follow-up period. For the pa-
tient whose serum phosphorous didn’t return to normal,
medical treatment would be arranged by endocrinology
physicians. Successful treatment was defined as signifi-
cant symptom improvement, normal serum phosphorus
and significant improvement or normalization of bone
mineral density at the last follow-up.
Statistical analysis
Data were analyzed using statistical software SPSS ver-
sion 16.0 (SPSS Inc, Chicago, IL). Fisher’s exact test was
used to test the difference of gender ratio, pathological
fracture rate, secondary operation rate and overall serum
phosphorus recovery rate between patients with soft tis-
sue tumors and bone tumors. Independent t-test was
used to test the difference of age, disease course, serum
phosphorus level, tumor size, operating time, bleeding
volume and follow-up period between patients with soft
tissue tumors and bone tumors. Statistically significant
differences were defined by p < 0.05.
Result
General characteristics of TIO patients
A total of 40 patients (24 males and 16 females) with an
average age of 44 ± 12 years (range of 20–67 years) were
identified in this cohort. All patients had symptoms ofbone pain, fatigue and difficulty walking. 75% (30/40) of
patients had at least one site of pathological fracture
caused by osteomalacia, primarily in ribs and lower ex-
tremities. Decreased serum phosphorus was seen in all
patients with an average of 0.44 ± 0.12 mmol/L (range of
0.27-0.66 mmol/L) (normal range of 0.81-1.45 mmol/L),
whereas serum calcium was normal in all patients with
an average of 2.31 ± 0.12 mmol/L (range of 2.10-
2.62 mmol/L). Alkaline phosphatase (ALP) was usually
elevated with an average of 277 ± 126U/L (range of 66-
759U/L). The average 1,25-dihydroxyvitamin D was 18.7 ±
11.8 pg/mL (range of 7.2-45.8 pg/mL). 24-hour urine phos-
phate and 24-hour urine calcium was 743 ± 468 mg (range
of 67-2171 mg) and 103 ± 68 mg (range of 1.2-281 mg),
respectively. And the average TMP/GFR was 0.39 ±
0.2 mg/dL (range of 0.12-0.99 mg/dL).
All 40 patients received 99Tcm-OCT (99Tcm-octreotide)
and 39 showed high expressions at different regions. The
tumor of the patient with negative 99Tcm-OCT (see
Table 1, patient 17) was discovered through physical
examination. And the tumor was located at subcutaneous
tissue of her right thigh. Six patients received PET/CT and
all showed hypermetabolic zone the same as 99Tcm-OCT
did. The tumors were located at soft tissue and bone in 25
and 12 patients, respectively. Both soft tissue and bone in-
vasion was observed in three patients. 90% (36/40) of the
tumors were in the lower extremities. The tumor location
for each patient is listed in Table 1.Primary surgical treatment
All patients received tumor resection or curettage by the
single senior doctor. 39 of 40 patients in this series were
primary surgical cases (except patient 19). The mean op-
erating time and mean bleeding volume was 103 ±
54 min (range of 20-260 min) and 127 ± 257 mL (range
of 20-1200 mL), respectively.
For soft tissue tumors, tumor resection was per-
formed. With the help of pre- and intra-operative
USG location, the tumor could usually be successfully
isolated despite its small size, with the exception of
patient 39. In three patients (patient 9, 14 and 19), the
tumors were close to the bone, so some cortical bone
tissues were removed together.
For bone tumors, tumor curettage and bone allograft
was performed in nine patients; tumor resection and
bone allograft was performed in one patient (patient 30);
tumor resection and total hip arthroplasty (THA) was
performed in two patients (patient 20 and 32).
For the three patients with both soft tissue and bone
tumors, tumor resection and curettage was attempted
first. In patient 13, the tumor was too widely involved,
thus only part of it was removed.
Table 1 Surgical options and effects for the treatment of patients with TIO
No. Gender/age (year) Tumor location Primary surgical procedure Histopathology SP level/recovery day Secondary surgery/surgical
procedure/SP level
1 F/42 soft tissue of right thigh Tumor resection MPNST Unnormalized No
2 F/41 soft tissue of left medial ankle Tumor resection GCTTS Normalized/8 days No
3 F/53 Bone tissue of right tibial plateau Curettage and bone allograft PMT Unnormalized Yes/Tumor resection and
prosthesis reconstruction/
Normalized
4 M/52 Bone tissue of medial condyle
of right femur
Curettage and bone allograft No tumor cells Unnormalized No
5 M/41 Soft tissue of right thigh Tumor resection PMT Normalized/6 days No
6 M/30 Bone and soft tissue of left
distal femur
Tumor resection and curettage
with cement reconstruction
Malignant PMT Unnormalized No
7 F/28 Soft tissue of left thigh Tumor resection PMT Normalized/7 days No
8 M/29 Soft tissue of right foot Tumor resection PMT Normalized/5 days No
9 M/57 Soft tissue of left leg Tumor resection PMT Normalized/6 days No
10 F/47 Soft tissue of left thigh Tumor resection PMTMCT Normalized/3 days No
11 M/57 Soft tissue of right thigh Tumor resection PMT Normalized/7 days No
12 M/27 Bone tissue of left greater trochanter Curettage and bone allograft PMT Unnormalized Yes/Curettage and
bone allograft/
Unnormalized
13 F/33 Bone and soft tissue of
right leg
Partial tumor resection PMT Unnormalized Yes/Amputation/normalized
(malignant PMT)
14 F/43 Soft tissue of left leg Tumor resection and partial
fibula resection
PMT Normalized/3 days No
15 F/34 Bone and soft tissue of
right leg
Tumor resection and curettage
with bone allograft
Malignant PMT Unnormalized Yes/Amputation/Normalized
16 M/43 Soft tissue of left forearm Tumor resection and partial
radius resection
PMT Normalized/12 days No
17 F/49 Soft tissue of right thigh Tumor resection PMT Normalized/5 days No
18 M/54 Soft tissue of right foot Tumor resection PMT Normalized/7 days No
19* F/29 Soft tissue of right foot Tumor resection PMT Unnormalized No
20 M/39 Bone tissue of right femur head Tumor resection and THA PMT Normalized/6 days No
21 F/48 Soft tissue of left foot Tumor resection PMT Normalized/3 days No
22 M/66 Soft tissue of left thigh Tumor resection PMT Normalized/2 days No
23 M/50 Bone tissue of left tibial plateau Curettage and bone allograft PMT Unnormalized Yes/Tumor resection and
prosthesis reconstruction/
unnormalized













Table 1 Surgical options and effects for the treatment of patients with TIO (Continued)
25 M/47 Soft tissue of right hip Tumor resection PMT Normalized/6 days No
26 F/59 Bone tissue of medial condyle of right femur Curettage and bone allograft No tumor cells Normalized/7 days Yes/Tumor resection and
prosthesis reconstruction/
normalized (PMT)
27 M/37 Soft tissue of left foot Tumor resection PMT Normalized/3 days No
28 M/50 Soft tissue of right arm Tumor resection PMT Normalized/7 days No
29 M/29 Soft tissue of right leg Tumor resection PMT Normalized/5 days No
30 M/20 Bone tissue of right ulna Tumor resection and bone allograft PMT Unnormalized No
31 M/50 Bone tissue of right tibial plateau Curettage and bone allograft No tumor cells Unnormalized No
32 F/47 Bone tissue of right femur head Tumor resection and THA PMT Normalized/6 days No
33 M/32 Bone tissue of right greater trochanter Curettage and bone allograft PMT Normalized/8 days No
34 F/38 Bone tissue of right greater trochanter Curettage and bone allograft PMT Normalized/7 days No
35 M/39 Soft tissue of left thigh Tumor resection PMTMCT Normalized/4 days No
36 M/63 Bone tissue of right distal femur Curettage and bone allograft PMT Normalized/8 days No
37 M/46 Soft tissue of right foot Tumor resection PMTMCT Normalized/2 days No
38 M/31 Soft tissue of right wrist Tumor resection PMT Normalized/5 days No
39 F/57 Soft tissue of left thigh No tumor was found No tumor cells Unnormalized No
40 M/62 Soft tissue of right leg Tumor resection hemangioma Normalized/7 days No
SP, serum phosphorus; MPNST, malignant peripheral nerve sheath tumor; GCTTS, giant cell tumor of tendon sheath; PMT, phosphaturic mesenchymal tumor; PMTMCT, PMT mixed connective tissue variant; THA, total
hip arthroplasty.













Table 2 Comparison of TIO patients with soft tissue






Gender (F:M) 10:15 4:8
Age (year) 46 ± 12 44 ± 13
Disease course (year) 4.8 ± 2.3 7.7 ± 7.0
Pathological fracture (%) 32(8/25) 17(2/12)
SP level (mmol/L)* 0.44 ± 0.11 0.46 ± 0.15
Longest diameter of tumor cm) 2.9 ± 1.4 2.2 ± 1.6
Primary operation message
Operating time (minute) 85 ± 42 109 ± 39
Bleeding volume (mL) 72 ± 138 153 ± 281
Secondary operation rate (%)# 0(0/25) 33(4/12)
Overall SP recovery rate (%) 88(22/25) 58(7/12)
Follow-up period (month) 35 ± 31 26 ± 34
SP, serum phosphorus.
*The normal range of SP level was 0.81-1.45 mmol/L.
#p < 0.05.
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10 patients required secondary surgery, including four
patients with malignant tumors (patient 1, 6, 13 and 15)
and six patients with bone tumors (patient 3, 4, 12, 23,
26 and 31). However, only six patients whose tumors
were not completely removed received secondary sur-
gery. Two patients (patient 3 and 23) with proximal tib-
ial tumor received tumor resection and prosthesis
reconstruction. One patient (patient 26) with distal
femur tumor received tumor resection of distal femur
and prosthesis reconstruction. One patient (patient 12)
with greater trochanter tumor underwent tumor curet-
tage and bone allograft again. The last two patients (pa-
tient 13 and 15) were diagnosed with malignant tumor
and underwent amputation. Other patients refused sec-
ondary surgeries.
Histopathology
Histopathology showed PMT in 34 patients (85%, 34/
40), of which three patients showed malignant PMT
[14]. Typical PMT are composed of spindled cells with a
highly vascular, embedded in a distinctive myxoid to
myxochondroid matrix, with “grungy” or flocculent cal-
cification. Osteoclast-like giant cells, cicrocysts, promin-
ent blood vessels, cartilage-like matrix and woven bone
were admixed with these small cells. Spindled cells of
benign PMT were of low nuclear grade and low mitotic
activity. For malignant PMT, spindled cells were charac-
terized as high nuclear grade, high cellularity and ele-
vated mitotic activity. Involvements of surrounding soft
tissue and cancellous bone were observed in these three
patients with malignant PMT. Other histopathologic
diagnoses included one malignant peripheral nerve
sheath tumor (MPNST), one giant cell tumor of tendon
sheath (GCTTS) and one hemangioma. No tumor tis-
sues were found in three patients. The pathological re-
sults of each patient are listed in Table 1.
Surgical results and follow-up
All patients were followed up for at least 12 months
(average: 43 months; range: 12–106 months). Serum
phosphorus returned to normal in 72.5% (29/40) of pa-
tients 5.6 ± 2.2 days (range of 2–12 days) after primary
surgery. After secondary surgery, serum phosphorus be-
came normal in three more patients. During a minimum
12 months follow-up period, significant clinical symp-
tom improvements and improvements of bone mineral
density were observed in all these patients. Thus suc-
cessful treatment was achieved in 80% of patients (32/
40). Eight patients still have decreased serum phos-
phorus and are receiving medical therapy. No patients
died during follow-up period.
Four malignant tumors were found in this cohort.
Two who received amputation achieved ensuing normalserum phosphorus (patient 13 and 15) and no tumor re-
currence was observed at the last follow-up; the other
two patients refused secondary operation and received
irradiation with a median radiation dose of 50 Gy for
five weeks, yet serum phosphorus did not become nor-
mal, despite that no distant metastasis was observed
showed by 99Tcm-OCT (patient 1 and 6).
Comparison of soft tissue tumor and bone tumor
Differences between patients with soft tissue tumors and
bone tumors were further compared (Table 2). No statis-
tical differences were found in gender ratio, age, disease
course, pathological fracture rate, serum phosphorus
level and tumor size. Although operating time of pri-
mary surgery was longer and bleeding volume was
greater in patients with bone tumors, this was not statis-
tically significant (p > 0.05). Secondary surgery rate was
significantly higher in patients with bone tumors (p <
0.05). Although the overall serum phosphorus recovery
rate in patients with soft tissue tumors was 88%, and
only 58% in bone tumors, no statistical significance was
found (p > 0.05). There was no difference in follow-up
period, either.
Discussion
80% (32/40) of our study cohort was treated successfully
through complete tumor removal surgery during an
average follow-up period of 43 months, including 29 pa-
tients after primary surgery and three after secondary
surgery. To gain complete remission of clinical symp-
toms, the tumor must be completely removed. For the
eight patients in this cohort whose serum phosphorus
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incompletely resected.
Soft tissue tumors usually had clear boundaries and
were well-encapsulated, so complete tumor resection
was straightforward. However, some tumors grew close
to bone, so sometimes it was difficult to distinguish
whether bone involvement existed; in these cases, some
bone tissue was removed. In fact, some cortical bone
was resected in three patients with soft tumors in this
series, and all of them completely recovered. The prog-
nosis for TIO patients with soft tissue tumor was good,
as 88% of patients achieved normal serum phosphorus
in this study. Of the three patients whose serum phos-
phorus did not return to normal, one had a malignant
tumor (patient 1), one had two previous surgeries at the
same site (patient 19), and one had an undetectable
tumor (patient 39).
Surgical treatment of bone tumors seemed to be much
more difficult, because it was often impossible to distin-
guish tumors with normal tissues during surgery. Pre-
operative preparation to determine curettage range was
important and tumor curettage with at least 5 mm from
tumor margins was suggested. However, only four of nine
patients were successfully treated after primary tumor cur-
ettage. Harbeck et al. [15] reported a 34-year-old male pa-
tient with TIO, whose tumor was located to the left greater
trochanter. Intraoperatively, a hand-held gamma probe
after administration of 111Indium pentetreotide 1 day be-
fore surgery clearly identified the tumor. This report pro-
vided us another way to identify the tumor during surgery.
Bone tumor resection appeared to be more effective
than curettage. In our study, two patients with femoral
head tumors received total femur head resection and
THA and both achieved successful treatment at the last
follow-up. In addition, three patients with failed primary
tumor curettage surgeries received secondary tumor re-
section and prosthesis reconstruction, two of which were
successfully treated. Nevertheless, these kinds of surger-
ies are often associated with greater morbidity with loss
of some limb function. Prosthesis related problems can-
not be ignored either. Less invasive treatment has been
reported in the literature. Hesse et al. [16] reported a
40-year-old woman with a tumor in her right femoral
head. To preserve her hip joint, CT-guided radiofre-
quency ablation was performed for two rounds.
Complete ablation was achieved, and no tumor recur-
rence was observed at one year follow-up. Tutton et al.
[17] reported another patient with a tumor in his right
iliac bone. CT-guided percutaneous ethanol ablation and
percutaneous cryoablation was performed. The tumor
was completely destroyed during 12 months follow-up.
Although these results are promising, larger sample sizes
are still needed. These are alternative methods and could
be considered for patients who refuse surgical treatment.Compared with widely tumor curettage surgery, tumor
resection surgery seemed to be a better choice for TIO.
However, considering anatomical and functional factors,
it’s difficult to perform tumor resection in all cases as
function could be severely compromised. Tumor curet-
tage could be considered in cases where surgical mor-
bidity was a concern and that attempting to curettage
beyond the expected tumor margin was recommended.
The mesenchymal tumor was typically benign whereas
malignant tumor was seen as well [2,12,14,18-21]. Four
malignant tumors were identified in our series of cases.
Of them, two received amputations, one received tumor
resection and the last one received tumor curettage. For
the last two patients, radiotherapy was arranged even
though only a little data had suggested it to be strongly
effective [19]. In fact, it was difficult to predict the be-
havior of these tumors only based on the morphologic
findings [2,18]. In our cohort, two of three tumors in-
volving both soft tissue and bone were proved to be ma-
lignant, which might be another characteristic to remind
us of the behavior of these tumors.
There were some limitations for this study. Firstly,
MRI or USG was not routinely performed during the
follow-up time for patients with unnormalized serum
phosphorus; instead, serum phosphorus and 1, 25-
dihydroxyvitamin D as well as bone mineral density were
regularly monitored. Only for those with decreased
serum phosphorus and intending for further surgical
treatment, residual tumors were examined. In addition,
the minimum follow-up time was only 12 months, thus
long term results could not be concluded. At last, sur-
geries were not always performed as surgeons planned.
Some patients refused further or more invasive opera-
tions, which might influence the overall efficacy assess-
ment of surgical treatment.
Conclusions
We report the surgical management of 40 cases of TIO
patients with extremity tumors, which is a relatively
large cohort for this rare disease. The majority of pa-
tients were treated successfully after tumor removal sur-
geries. Complete tumor resection was the more effective
surgical approach. When this was not feasible, tumor
curettage with wide curettage margins could be consid-
ered, though persistent or recurrent disease might be
more likely.
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